Poor
Not Aligned
Patient Risk:
Moderate
Summary
The response includes multiple statements that conflict with, or are not supported by, the provided FDA label excerpts (notably infection incidence percentages, pregnancy/liver/WBC/live vaccine guidance, and dosing adjustments based on infection risk). Several safety/monitoring requirements (TB evaluation/testing) are supported.
Category Scores
Accurate Statements
Kevzara is associated with serious and sometimes fatal infections, including opportunistic infections such as tuberculosis, candidiasis, and pneumocystis.
5.1 Serious Infections
Avoid use of Kevzara in patients with an active infection, including localized infections.
5.1 Serious Infections
Evaluate patients for tuberculosis (TB) risk factors and test for latent infection prior to initiating treatment with Kevzara.
5.1 Serious Infections (TB evaluation/testing prior to initiation)
Kevzara should not be administered to patients with active TB.
2.1 General Considerations Prior to Administration (TB evaluation; 'KEVZARA should not be administered to patients with active TB.')
Hold Kevzara if a patient develops a serious infection or an opportunistic infection until the infection is controlled.
2.6 Dosage Modifications for Infections; 5.1 Serious Infections
Close monitoring for signs and symptoms of infection during treatment is recommended.
5.1 Serious Infections (closely monitor...)
Infection-resistance may be lowered; patients should contact their physician for symptoms suggesting infection.
17 Patient Counseling Information (Infections)
Unsupported Statements
Infections (upper respiratory, urinary) affect 40-50% of Kevzara users.
The provided label excerpts do not report 40–50% infection rates by site (upper respiratory, urinary). Only general infection rates per 100 patient-years are provided.
Serious infections such as pneumonia occur in 3-5% of Kevzara users.
The provided excerpts report rates per 100 patient-years (events per 100 patient-years), not incidence percentages 3–5% of users.
Elevated liver enzymes occur in 20-30% of Kevzara users.
Liver enzyme incidence percentages are not present in the supplied label excerpts.
Low neutrophils occur in 10-15% of Kevzara users.
Neutropenia incidence percentages are not present in the supplied label excerpts.
Injection-site reactions are an adverse effect of Kevzara.
Injection-site reactions are not included in the provided label excerpts.
Bloodwork monitoring is required for Kevzara.
The supplied excerpts specifically mention TB evaluation/testing and monitoring for infection/TB signs, but do not state a general requirement for bloodwork monitoring.
Kevzara is riskier in pregnancy.
Pregnancy-related risk statements are not present in the supplied label excerpts.
Kevzara should be avoided in pregnancy.
Pregnancy guidance is not present in the supplied label excerpts.
Kevzara should be avoided with live vaccines.
Vaccine guidance is not included in the supplied label excerpts.
Kevzara should be avoided in liver disease.
Liver disease avoidance guidance is not present in the supplied label excerpts.
Kevzara should be avoided in low white blood cell counts.
Avoidance based on low WBC counts is not present in the supplied label excerpts.
For RA, adults take Kevzara as a 150 mg dose if side effects occur or liver enzymes rise.
The provided excerpts do not describe dosing adjustments for side effects or liver enzyme elevations.
Doctors adjust Kevzara dosing based on infection risk or blood counts.
The provided excerpts do not describe dosing adjustments based on infection risk or blood counts; they describe holding treatment for serious/opportunistic infections and TB evaluation/monitoring.
Contradictions
Low
AI Statement
Kevzara is FDA-approved for moderate-to-severe RA since 2017.
Label Reference
Not verifiable/unsupported by provided FDA label excerpts (no approval date or indication history included in the supplied sections).
Low
AI Statement
For RA, adults take Kevzara as a 200 mg subcutaneous injection every two weeks.
Label Reference
Not verifiable/unsupported by provided FDA label excerpts (dosage schedules are not included in the supplied sections).
Low
AI Statement
Kevzara specifically inhibits the IL-6 pathway.
Label Reference
Not addressed in the supplied FDA label excerpts.
Important Omissions
When TB risk evaluation/testing is positive (latent TB), the label excerpt states that clinicians should consider treating latent TB before initiating Kevzara (and consult TB expertise in some cases).
Importance:
Moderate
The label excerpt notes the approach to viral reactivation and unknown Hepatitis B reactivation risk because at-risk patients were excluded; the response does not mention this.
Importance:
Low
Safety Assessment
Potential Patient Risk:
Moderate
Several quantitative safety assertions and multiple avoidance/guidance statements (pregnancy, live vaccines, liver disease, low WBC) are unsupported by the provided label excerpts, which could lead to inaccurate risk communication. Supported guidance (avoid active infection, TB evaluation, close monitoring, and holding for serious/opportunistic infection) is present, mitigating risk.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Not Aligned
Primary Issue
Multiple safety-related numeric claims and population-specific avoidance guidance are not supported by the supplied FDA label excerpts, and some dosing-related adjustment statements are not supported.
Suggested Improvement
Limit infection/TB statements to what the provided label excerpts support (e.g., avoid active infection, perform TB risk evaluation/testing, hold therapy for serious/opportunistic infections, close monitoring). Remove or qualify unsupported percentage-based incidence claims and remove unsupported pregnancy/live-vaccine/liver-disease/low-WBC avoidance assertions unless supported by additional label sections not provided here.